We recently showed that vaccination with a 7-valent pneumococcal conjugate vaccine (PCV7) followed by a 23-valent pneumococcal polysaccharide vaccine (PPSV23) failed to prevent new episodes of acute otitis media (AOM) in previously unvaccinated toddlers and children with a history of recurrent AOM. We describe in detail the impact of pneumococcal vaccinations on nasopharyngeal carriage of S. pneumoniae in this study population.
years, carriage rates decrease, coinciding with a natural increase of antibodies against the capsular polysaccharide antigens of pneumococci and a natural decrease in the risk for pneumococcal diseases [4] .
Pneumococcal conjugate vaccines have been shown to reduce the rate of nasopharyngeal (NP) carriage of conjugate vaccine-type (CVT) S. pneumoniae among healthy infants and toddlers [5] [6] [7] [8] . This may partly explain the observed decrease in the incidence of upper and lower respiratory tract infections and AOM [9] [10] [11] [12] . In several studies, however, decreased rates of CVT S. pneumoniae carriage after vaccination coincided with increased rates of nonconjugate vaccine serotype (NCVT) carriage [5, 6, 8] . Most likely, this shift from CVT to NCVT S. pneumoniae is due to replacement Figure 1 . Vaccination scheme and time points at which nasopharyngeal sampling and immunological evaluation (measurement of levels of antipneumococcal antibodies against 7-valent pneumococcal conjugate vaccine [PCV7] serotypes) were performed. Children aged 12-24 months received PCV7 twice and children aged 25-84 months received PCV7 once before receipt of the booster 23-valent pneumococcal polysaccharide vaccine. Control subjects received hepatitis vaccines over a similar time schedule. [13, 14] . To our knowledge, no significant increase in the rate of NCVT S. pneumoniae carriage in patients with invasive disease has been reported [15] . For mucosal infections such as AOM, however, infants vaccinated with heptavalent pneumococcal conjugate vaccine showed a 27%-33% higher rate of AOM caused by NCVT S. pneumoniae than did control subjects, as well as a significant decrease in the rate of AOM caused by CVT S. pneumoniae [10, 16] . Serotype replacement in the nasopharynx, therefore, may have a larger impact on mucosal infections than on invasive disease [17] .
To date, the reported clinical efficacies in AOM and carriage studies of pneumococcal conjugate vaccines have mainly focused on healthy infants and toddlers [9] [10] [11] 16] . One study published data on the clinical efficacy of a 7-valent pneumococcal conjugate vaccine (PCV7 [Prevnar; Wyeth]) in children with recurrent AOM [18] . In this study, combined vaccination with PCV7 and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumune; Wyeth]) had no effect on the clinical recurrence rate of AOM. It is possible that phenomena such as pneumococcal replacement in the nasopharynx after pneumococcal vaccination strongly influence the clinical outcome in the prevention of mucosal infections, particularly in children prone to recurrent respiratory tract infections. We now describe in detail the impact of vaccination with PCV7 followed by a booster PPSV23 vaccination on rates of NP carriage of S. pneumoniae among children aged 1-7 years with a history of recurrent AOM in a comparison of the different pneumococcal vaccination schemes used in the study.
SUBJECTS, MATERIALS, AND METHODS
NP carriage of S. pneumoniae was studied in a double-blind, randomized, controlled trial that was conducted between April 1998 and January 2002. This study was part of a larger study of the clinical efficacy of pneumococcal vaccination against AOM in children with recurrent AOM. Overall results of this study, as well as information on subjects, materials, and methods, have recently been published elsewhere [18] . The study was undertaken in accordance with the ethical standards of the responsible committees of both participating hospitals and with the Helsinki Declaration of 1975, as revised in 1983.
Inclusion criteria for the study were у2 AOM episodes in the year before study entry and age of 1-7 years at the time of the first study or control vaccination. Exclusion criteria for the study were primary or secondary immunodeficiency, cystic fibrosis, immotile cilia syndrome, craniofacial malformation (such as cleft palate), abnormal chromosomal findings (such as Down syndrome), and severe adverse events during previous vaccinations. Vaccination schemes and the timing of NP sampling and antipneumococcal antibody evaluation are shown in figure 1 .
Vaccinations. The children were randomized to receive either PCV7, followed by PPSV23, or hepatitis A or B vaccines. PCV7 contained 2 mg each of saccharides of pneumococcal serotypes 4, 9V, 14, 18C, 19F, and 23F and 4 mg of 6B, coupled to the protein carrier CRM197. The PPSV23 doses consisted of 25 Wire & Equipment Co.) that was inserted into the nostrils and advanced until resistance was found. The swabs were inoculated directly in Stuart's transport medium and plated within 6 h onto two 5% sheep blood agar plates, a 5% sheep blood agar plate with 5 mg/L gentamicin, and a chocolate agar plate. Agar plates were incubated at 37ЊC for 48 h. The blood agar plates were incubated aerobically and anaerobically, and the blood agar plate with gentamicin and the chocolate agar plate were incubated with increased CO 2 levels. Identification of S. pneumoniae, H. influenzae, and M. catarrhalis was based on colony morphology and conventional methods of determination. Initially, 4 S. pneumoniae colonies from each plate were serotyped. Because the 4 colonies were found to be identical in the first 20 patients, we later serotyped 1 colony from each plate. Serotyping was performed with the capsular swelling method (i.e., the Quellung reaction) by microscopy with commercially available antisera (Statens Seruminstitut).
Vaccine immunogenicity. Blood samples that were obtained from randomly selected patients in the pneumococcal vaccine group were analyzed by ELISA for serum IgG antibodies to the 7 pneumococcal serotypes in the conjugate vaccine [19] .
Statistical analysis. In children with a positive S. pneumoniae culture, carriage of CVT and NCVT S. pneumoniae and individual serotypes was analyzed both at 7 months after conjugate or control vaccination(s) and after booster polysaccharide or control vaccination. For each individual, only the first pneumococcal culture performed at 14, 20, or 26 months after the polysaccharide/control vaccination was included in the analysis.
Proportional differences in carriage of S. pneumoniae, H. influenzae, and M. catarrhalis at enrollment, after conjugate vaccination alone, and after booster with the polysaccharide vaccine were analyzed using x 2 tests or Fisher's exact tests, when appropriate. Differences between IgG anti-pneumococcal antibody responses in children aged 12-24 months and children aged 25-84 months were analyzed with the Mann-Whitney U test. We judged to be statistically significant. P ! .05
RESULTS
A total of 383 children were enrolled; 190 children received pneumococcal vaccinations, and 193 received hepatitis A or B control vaccinations. NP swab specimens were obtained from a similar number of children in the pneumococcal and control vaccine groups (185, 182, 175, 141, and 121 children vs. 190, 174, 169, 140, and 118 children at study entry and at 7, 14, 20, and 26 months, respectively, after the first vaccine dose). Both groups were comparable with respect to age, sex, number of previous AOM episodes, and environmental risk factors for AOM (such as day care) (table 1). More than 95% of all children completed the vaccination scheme, and the median follow-up duration in both groups was similar [18] .
Pneumococcal carriage at baseline. At the time of enrollment, 185 (49%) of the 375 NP swabs tested positive for S. pneumoniae. Of all swab cultures positive for pneumococci, 53% yielded isolates that belonged to the CVT group: 13% were serotype 19F, 12% were serotype 6B, 11% were serotype 23F, 9% were serotype 14, 6% were serotype 9V, 1% were serotype 18C, and 1% were serotype 4. Of the remaining isolates, 45% were found to be NCVT pneumococci, of which crossreactive serotypes 6A (11%) and 19A (3%) and non-crossreactive serotypes 11 (4%) and 3 (3%) were the most frequent. A total of 2% of all pneumococcal isolates were not typable. The rate of pneumococcal carriage at baseline was not influenced by age (i.e., 12-24 vs. 25-84 months) or by the number of previous AOM episodes (i.e., 2-3 vs. у4 episodes) in the year before the first vaccination (data not shown). However, the relative contribution of CVT pneumococci tended to be less in children aged у25 months (49 [48%] of 102 pneumococcal isolates), compared with children in the younger group (age, 1-2 years; 49 [59%] of 83 pneumococcal isolates;
). Even after the age of 36 months, 25 (42%) of the 60 P p .14 isolated pneumococci were still CVT S. pneumoniae. Regardless of age, the relative contribution of CVT and NCVT S. pneumoniae was not influenced by the number of previous AOM episodes (results not shown).
Impact of vaccination on pneumococcal carriage. Seven months after administration of the first PCV7, the percentage of children carrying S. pneumoniae (85 [47%] of 182 recipients of pneumococcal vaccine) was found to be less than that for recipients of control vaccine (101 [58%] of 174;
). With P p .04 respect to age, this difference was found to be significant only in children 12 years of age at the time of the first vaccination (47% of pneumococcal vaccine recipients vs. 57% of control vaccine recipients;
). After receipt of PPSV23, the over-P p .04 all rate of pneumococcal carriage was not reduced, compared with control vaccinees, remaining at ∼50% in both age groups during the follow-up period (figure 2).
The relative contribution of CVT S. pneumoniae to all pneumococcal isolates 7 months after the first vaccination was lower in pneumococcal vaccinees (33 ). This difference was most P p .001 pronounced in those children who were first vaccinated at 12-24 months of age (25% vs. 52%; ) (table 2) . Among P p .002 children enrolled between 2 and 7 years of age, CVT carriage rates decreased over time among both treatment groups, and the observed difference in CVT contribution was less between pneumococcal vaccinees and control subjects (25% vs. 38%;
). P p .06 Both 7 months after PCV7 vaccination(s) alone, as well as after PPSV23 vaccination, the decreased rate of CVT S. pneumoniae carriage occurred in parallel with an increase in the rate of NCVT S. pneumoniae carriage (table 2). Seven months after administration of PCV7, 45 (53%) of 85 pneumococcal isolates proved to be NCVT, compared with 46 (46%) of 101 pneumococcal isolates in control subjects ( ). After ad-P p .31 ministration of PPSV23, 103 (73%) of 141 pneumococcal isolates were NCVT, compared with 78 (54%) of 144 pneumococcal isolates in control subjects ( ). The difference in P p .001 NCVT carriage between both treatment groups was more pronounced in children aged 12-24 months (73% vs. 48%; P p ) than in older children (73% vs. 59%; ). .004 P p .07 Figure 3 shows the relative contributions of CVT and NCVT S. pneumoniae to overall pneumococcal carriage during the entire follow-up period, according to age at the time of first vaccination. The lower impact of pneumococcal vaccination on pneumococcal NP carriage in children enrolled between 2 and 7 years of age held true when this group was stratified further into those aged 25-36 months and those aged 37-84 months at the time of first vaccination.
With respect to the impact of pneumococcal vaccinations on the individual CVT pneumococci in children carrying S. pneumoniae 7 months after the first dose of PCV7, only the decrease in the rate of conjugate vaccine serotype 14 carriage was found to be statistically significant ( ) in children aged 25-84 P p .04 months at the time of first vaccination (table 2). After receipt of PPSV23, the reduction in the carriage of serotype 14 and other individual CVT serotypes did not reach statistical significance. The increase in NCVT S. pneumoniae carriage was statistically significant for serotype 11 only in the youngest children after receipt of PPSV23 ( ) (table 2) . With P p .007 respect to possible cross-protection between different serotypes of the same serogroup, no protective effect of pneumococcal vaccination for serotype 6A was observed. Serotypes 19A, 23A, and 23B were only rarely cultured.
Vaccine immunogenicity. After complete vaccination, geometric mean IgG concentrations reached values far greater than 1.0 mg/L and were roughly similar in children first vaccinated at age 12-24 months and in older children for all CVT serotypes, with the exception of 6B, which remained !1.0 mg/L in the youngest group (table 3) .
NP carriage of H. influenzae and M. catarrhalis. At study entry, H. influenzae and M. catarrhalis were found in the nasopharynx of 58% and 50% of children, respectively. With respect to age and history of AOM, only carriage of M. catarrhalis was influenced by age: the carriage rate among children aged 12-24 months was 57%, and the rate among those aged 25-84 months was 44% ( ). Pneumococcal vaccinations did P p .02 
DISCUSSION
We describe for the first time the impact of PCV7 followed by PPSV23 on NP carriage of S. pneumoniae in a group of toddlers and children aged 1-7 years with a history of recurrent AOM. Overall pneumococcal NP carriage rates among these children did not diminish after pneumococcal vaccinations during 2 years of follow-up. However, particularly in children first vaccinated at age 1-2 years who received PCV7 twice before PPSV23, a shift from CVT to NCVT S. pneumoniae was induced. In older children, who received PCV7 only once before PPSV23, the impact of pneumococcal vaccinations on pneumococcal carriage was far less pronounced. Because both age groups showed a similar contribution of CVT S. pneumoniae to NP carriage at start of the study, this does not explain the decreased vaccine influence after 2 years of age. Also, both age groups achieved roughly similar serum levels of IgG antibodies to pneumococcal serotypes by pneumococcal vaccinations, except for IgG titers against serotype 6B, which remained !1 mg/ L in the youngest group. We therefore assume that the greater shift from CVT to NCVT in children aged 1-2 years is primarily explained by the difference in vaccination schemes; the younger patients received 2 and the older patients 1 dose of PCV7. This is underlined by the fact that vaccination influence was already nearly absent in pneumococcal vaccinees aged 25-36 months.
The T cell-dependent characteristics of a conjugate vaccine result in recruitment of new memory B cells, the levels of which increase after each vaccination, whereas a polysaccharide vaccine may only trigger preexisting memory cells [20] . At the mucosal level, the extra B cell recruitment may result in a better opportunity to boost mucosal immunity by transient natural contacts with conjugate vaccine serotypes. Nurkka et al. [21] previously described an increase in salivary IgG several months after a final vaccination with PCV7 in several children, whereas only 1 child showed a late increase in salivary IgG after a booster polysaccharide vaccine. Thus, although both PCV7 and PPSV23 booster vaccinations significantly increase quantitative serum IgG responses, the conjugate vaccine may be superior in inducing mucosal memory for the conjugate vaccine serotypes. Also, other qualities, such as antibody affinity, may be superior after extra conjugate vaccinations, compared with the polysac- charide booster, which may also lead to better mucosal immunity [22] . Pneumococcal polysaccharide vaccine is known to have little influence on NP pneumococcal colonization [23, 24] . Our study shows that it also fails to prohibit the increase of NP carriage of NCVT pneumococci, such as serotype 11, despite induction of good serum IgG levels [18] , and apparently does not affect the NP flora of those serotypes included in PPSV23 but not in PCV7. Hypothetically, a polysaccharide booster might even frustrate future antibody responses at the mucosal site during subsequent natural challenge with polysaccharides [25] . After the conjugate vaccinations, we saw an initial decrease in pneumococcal carriage just before booster vaccination with PPSV23, particularly in children 12 years of age. After administration of the polysaccharide booster, however, pneumococcal carriage rates subsequently increased again to levels similar to those before vaccinations and identical to those in control subjects. We do not think, however, that this failure to reduce pneumococcal carriage is due to the polysaccharide booster because, after pneumococcal vaccination in healthy infants and toddlers, overall pneumococcal carriage was also not affected [6] [7] [8] .
In our risk group for AOM, the baseline NP pneumococcal carriage rate was ∼50%, which is in line with average carriage rates for similar age groups worldwide [1] . PCV7 serotypes comprised 53% of the pneumococcal strains isolated from the nasopharynx, which is similar to recent Finnish data on NP pneumococcal carriage in children [26] . Whether otitis-prone children do have higher pneumococcal carriage rates during periods of health, compared with non-otitis-prone children who are healthy, is still a matter of debate [27] . However, in contrast with a recent report in The Netherlands [28] , in our study, older children aged 3-7 years did not show decreasing overall pneumococcal colonization rates, not even after 2 years of follow-up. It may be speculated that older children with recurrent otitis still have high pneumococcal carriage rates because they are unable to eradicate pneumococci from their nasopharynx or to prevent new acquisition because of minor immunodeficiency [18, [29] [30] [31] [32] [33] .
Despite low mean serum IgG concentrations (!1 mg/L) for serotype 6B, a significant decrease of 50% in the carriage of serotype 6B was noted in the youngest age group. We found a lack of influence of pneumococcal vaccinations on carriage of the cross-reactive serotype 6A, most probably related to the low anti-6B antibody response. Väkeväinen et al. [34] showed that, on average, 2-6 times more anti-6B antibodies were needed for 50% opsonophagocytic killing of the type 6A than the type 6B strain. A low IgG response against serotype 6B after PCV7 vaccination, which was similar in both younger and older patients in our study group, was also reported in other small groups of infection-prone patients [35, 36] . A third study involving otitis-prone children could not confirm this observation [37] .
The observed NP shift from CVT to NCVT pneumococci after pneumococcal vaccination in our study population seems to be due largely to replacement (Bogaert et al., unpublished data). Apart from replacement by NCVT pneumococci, pneumococcal vaccinations did not influence carriage of other potential AOM pathogens, such as H. influenzae and M. catarrhalis.
Clinically, we reported elsewhere that no protective effect of combined pneumococcal conjugate and polysaccharide vaccination was found for the prevention of AOM after 1 year of age in children with a history of AOM [18] . In the youngest children, in particular, this may be due to the replacement of CVT S. pneumoniae by NCVT S. pneumoniae. After 2 years of age, pneumococcal carriage was less influenced by vaccination and, therefore, may not have affected the incidence of AOM.
The results of our study show that, in high risk groups, not only should vaccine immunogenicity studies be performed, but clinical efficacy studies, combined with the evaluation of the bacterial changes in NP colonization, should also be done to provide insight into the impact of vaccinations. Despite adequate quantitative serum IgG levels, at least 2 conjugate vaccinations seem to be mandatory for reduction of NP carriage of CVT serotypes. To obtain higher serum IgG levels for serotype 6B, a third or perhaps fourth conjugate vaccination may be required at all ages, which may only then result in reduction of carriage of serotype 6A. Booster vaccination with a polysaccharide vaccine does not seem to enhance mucosal immunity. The results of this study should be kept in mind when recommending pneumococcal vaccinations for mucosal disease, such as AOM, but also for lower respiratory tract infec-tions, such as pneumonia, for children 11 year of age, particularly those in at-risk groups.
